PT-141 10 mg

About PT-141

PT-141 is the code name Palatin Technologies used for bremelanotide during development, when it was made as an analog of melanotan II.⁷³ It is a chain of seven amino acids, partly closed into a ring, that ends in a free acid where melanotan II ends in an amide.¹⁸

The Vyleesi label describes bremelanotide as a melanocortin receptor agonist that activates several receptor subtypes without selectivity, most potently MC1R and then MC4R.¹ The same label says the way it improves HSDD in women is unknown.¹

FDA approved bremelanotide in June 2019 as Vyleesi, a 1.75 mg/0.3 mL prescription autoinjector for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).²¹ The label says it is not indicated for HSDD in postmenopausal women or in men, or to enhance sexual performance.¹

This page lists PT-141 for sale as a 10 mg research vial. It is not Vyleesi, and it has no approved application.⁵ Researchers who buy PT-141 online here receive the freeze-dried solid; diluent and supplies are separate. The PT-141 price is $40 per vial. The vial sits in the sexual health peptides category of the peptide shop. For background on the compound, read What is PT-141?.

Research highlights

• In two 24-week phase 3 trials of 1,267 premenopausal women with HSDD, desire scores rose 0.30 and 0.42 points more than with placebo.⁹
• The same trials found no significant rise in satisfying sexual events versus placebo (label).¹
• Nausea affected 40% of women on bremelanotide versus 1.3% on placebo, and 18% stopped because of side effects versus 2% (label).¹
• Blood pressure rose by up to 6 mmHg systolic after each dose, with heart rate down by up to 5 beats per minute, usually resolving within 12 hours (label).¹
• Patches of darker skin appeared in 1% of phase 3 patients using up to 8 doses a month, and in 38% of patients given it daily for 8 days in another study (label).¹
• Two 2004 reports on men found that single injected or nasal doses gave significantly greater erectile responses than placebo; the abstracts do not give study sizes. No use in men is approved.¹⁰⁶¹
• In female rats, PT-141 increased solicitation (courtship) behavior without changing lordosis or pacing.¹¹

Regulatory status

Vyleesi (NDA 210557) is a prescription drug and the only FDA-approved bremelanotide product.² No approved application covers PT-141 sold for research.⁵ On August 24, 2026, FDA warning letters to at least two online peptide sellers named PT-141 among products the agency called unapproved new drugs.¹²⁵ In both letters, FDA said labels such as "research use only" did not change its conclusion, because evidence from the sellers' websites showed the products were intended as drugs for human use.¹²⁵ This vial is sold for laboratory research, and nothing on this page is a direction for human use.

Handling and storage

The vial holds a dry solid, and bacteriostatic water is a separate item. No FDA-reviewed reconstitution directions exist for this product.⁵ Our guide How to reconstitute a peptide vial covers sterile technique, the reconstitution calculator does the concentration arithmetic, and How to store peptides covers storage. Lab handling supplies include bacteriostatic water, 3 mL Luer-Lok syringes, 18G 1-inch needles, insulin syringes and alcohol swabs. For larger research orders, see wholesale and bulk peptides.